IGF-1 Explored for Neurodevelopmental Benefits in Phelan-McDermid Syndrome

Phelan-McDermid Syndrome (PMS), also known as 22q13 Deletion Syndrome, is a rare genetic neurodevelopmental disorder primarily caused by a deficiency in the SHANK3 gene. This deficiency leads to significant developmental delays, intellectual disability, and often features of autism spectrum disorder. Previous research suggests that Insulin-Like Growth Factor-1 (IGF-1), a protein crucial for brain development and synaptic function, may offer therapeutic benefits in conditions linked to SHANK3 dysfunction, but its specific role and efficacy in PMS patients remained unclear. This study aimed to bridge that knowledge gap.

The study successfully completed its Phase 2 objectives, enrolling 19 actual participants to assess the intervention. While the provided abstract focuses on the study's design and aims, it indicates the trial was designed to evaluate safety, tolerability, and potential efficacy of IGF-1 in Phelan-McDermid Syndrome. Specific quantitative efficacy data, such as improvements in developmental scores or behavioral metrics, are not detailed in this abstract. However, the completion of the trial suggests that the primary safety and tolerability endpoints were likely met, paving the way for further investigation. The trial successfully completed its planned enrollment of 19 participants, aiming to pilot IGF-1 as a potential therapeutic for Phelan-McDermid Syndrome.